



**FEDERAL UNIVERSITY OF PELOTAS
POST-GRADUATE PROGRAM IN EPIDEMIOLOGY**



PLATINO STUDY – VENEZUELAN SURVEY



REPORT

This report was prepared by

**ANA MARIA BAPTISTA MENEZES
CESAR GOMES VICTORA**

On behalf of the Venezuela Platino Study Team

Dra. Maria Montes de Oca

Dr. Carlos Talamo

Principal Investigators

Dra. Dolores Moreno

Co-investigators

Statistical analyses: Pedro Curi Hallal, MSc

Sampling advice: Dra. Dulce María Meza

Anthropometry supervisors: Coromoto Baduet and. Albertina Bracho

Field supervisors: Yumaira Hernández y María Elisa Lozada

Spirometry supervisor: Dra. María Nelly Márquez

We would like to thank the support provided by ALAT and BI, as well as the continued participation of the PLATINO Steering Committee, Advisory Committee and Executive Committee.

**PELOTAS, BRAZIL
2005**



1. INTRODUCTION

The prevalence of Chronic Obstructive Pulmonary Disease (COPD) in many developed countries appears to be increasing (Hurd, 2000; Pauwels, 2000; Petty, 2000). There is also some evidence from Latin America that COPD is a growing cause of death, but information on prevalence is scant (Brasil, Datasus). To obtain a detailed picture of the global distribution of this severe condition, it is necessary to know its prevalence in less developed countries. It is possible that, due to the high frequency of smoking - the main risk factor for COPD - in these countries, this disease may represent a major public health problem that has not yet been recognized as such.

The PLATINO study is aimed at measuring COPD prevalence in major cities in Latin America. So far, studies have been completed in São Paulo, Mexico, Montevideo, Santiago and Caracas.

The main objective of the Platino study is to measure COPD prevalence in major Latin American metropolitan areas. The specific objectives are:

- ✓ To measure and compare COPD prevalence using different definitions, including ATS, ERS, GOLD, fixed ratio and symptomatic criteria;
- ✓ To measure the prevalence of known risk factors for COPD including socio-economic status, smoking, type of cigarette smoked, indoor biomass pollution, work exposure, environmental pollution, genetic factors and history of severe respiratory disease in childhood;
- ✓ To describe the distribution of COPD according to age, sex, smoking and the presence of other risk factors;
- ✓ To describe the main clinical symptoms reported by subjects diagnosed with COPD;
- ✓ To assess the sensitivity and specificity of COPD clinical findings, using lung function as the “gold standard”;
- ✓ To compare COPD prevalence in Latin America with that reported from other countries (mainly developed ones);
- ✓ To correlate the subject’s awareness of suffering from COPD with actual diagnosis;
- ✓ To describe how this disease is being managed in terms of drug therapy, clinical and laboratory investigations, and other relevant aspects;
- ✓ To describe the social and economic consequences of COPD, in terms of work limitations, absenteeism and other relevant issues.

A full description of the rationale and methodology of the study is available in the original study proposal (Platino Project, 2002) and in our website (www.platino-alat.org).


This report describes the main results of the Caracas survey, the fourth site where the project has been completed.

2. METHODOLOGY

2.1. Design of the study

A cross sectional design was used in order to provide a representative sample of adults aged ≥ 40 years living in the Metropolitan District of Caracas City, through a stratified two-stage cluster sampling (Figure 1).

Figure 1 – Metropolitan District (Caracas). Selection of the 68 blocks (Primary Sampling Units) stratified by County and social-oriented implicit stratification.



2.2. Sampling

The sample size calculations required 800 subjects in order to estimate a prevalence of up to 30% with a margin of error of less than 4 percent points (see original proposal). To allow for non-response we aimed at obtaining 68 census tracts in the Metropolitan District of Caracas City, and to select 15 households, on average, from each selected sampling tract.

Based on the most recent census (carried out in 2001), we expected, on average, 1.15 persons aged 40 years or more per household.

For sampling purposes, the Metropolitan District was divided into five strata following the five counties comprising the District: Libertador, Baruta, Chacao, El Hatillo and Sucre.

Sampling frame

The sampling design was based on the cartographic and demographic data of the XIII population census carried out in Venezuela in 2001. A sampling frame was built from this information and the primary sampling units (PSU) or sampling tracts (Blocks comprising each operative-oriented census tracts) were classified into five groups according to the following method:

For each Census Tract, the percentage of households classified as “non-poor”, “poor” and “extremely poor” was calculated following the widely-used “Unmet Basic Needs” methodology. Next, the K-means method (a mathematical non-hierarchical classification technique) was used for classifying the census tracts into five groups. Table 1 shows the number of houses by county and final classification group.

Within each selected tract, the cartographical census information was updated before households were selected.

Table 1 - Total of Metropolitan District Houses
By County and Classification Group

| Group | Distrito Capital (Libertador) | Miranda State´s Counties | | | | TOTAL |
|-------|-------------------------------|--------------------------|--------|------------|---------|---------|
| | | Baruta | Chacao | El Hatillo | Sucre | |
| 1 | 191,519 | 52,396 | 17,878 | 8,617 | 52,973 | 323,383 |
| 2 | 135,806 | 7,684 | 1,681 | 2,398 | 28,107 | 175,676 |
| 3 | 85,308 | 6,908 | 437 | 1,007 | 40,428 | 134,088 |
| 4 | 33,137 | 1,340 | 310 | 204 | 10,611 | 45,602 |
| 5 | 7,755 | 2,415 | 0 | 1,334 | 4,952 | 16,456 |
| TOTAL | 453,525 | 70,743 | 20,306 | 13,560 | 137,071 | 695,205 |

Selection of Primary Sampling Units

Within each county, PSU's were ranked by social classification and geographical location. Then, a systematic selection process with probability proportional to the number of households in each block was carried out in order to select the desired number of tracts in each stratum (see Table 2).

Table 2
Total of Primary Sampling Units selected by County (strata)

| Tipo de Segmento Censal | Distrito Capital | Municipios del Estado Miranda | | | | TOTAL |
|-------------------------|------------------|-------------------------------|--------|------------|-------|-------|
| | | Baruta | Chacao | El Hatillo | Sucre | |
| TOTAL | 44 | 7 | 2 | 2 | 13 | 68 |

2.2.2. Sampling of the households

Within each selected tract, a systematic random process following the physical distribution of the households was used to select approximately 15 of them. The number of households selected in each tract was adjusted to take into account the observed changes in the number of households since the demographic census. Finally, all adults aged 40 years or more living in each household selected were included in the study; if there were no adults in this age range in the household, it was not included in the survey and there was no replacement.

2.3. Variables

2.3.1. Dependent variable

The main outcome of the study was the prevalence of COPD measured by spirometry after bronchodilator use, according to the following criterion: $FEV_1/FVC < 70\%$, where FEV_1 is the forced expiratory volume in the first second, and FVC is forced vital capacity (Viegi, 2000).

Prevalence of COPD was also analyzed according to other criteria:

- ✓ Global Obstructive Lung Disease (GOLD, 2001) - $FEV_1/FVC < 70\%$ and $FEV_1 < 80\%$ predicted;

- ✓ European Respiratory Society (ERS, 1993) - FEV1/FVC <88% of predicted in men and < 89% predicted in women;
- ✓ American Thoracic Society (ATS, 1994) - FEV1/FVC below 5th percentile and FEV1<100% predicted;

For the analyses of lung function measurements, the NHANES Mexican-American reference values were used (NHANES, 1994).

Reported symptoms were also evaluated: these included the prevalence of chronic bronchitis (cough with phlegm for at least three months a year in the last two years); breathlessness due to exercise; and wheezing in the last 12 months (Ciba Foundation Guest Symposium, 1959).

Subjects were also asked whether they ever had a medical diagnosis of chronic bronchitis, emphysema or COPD.

2.3.2. Risk factors

The following risk factors were investigated:

- ✓ sex - dichotomous variable: male or female.
- ✓ age - discrete variable: years completed until the date of the interview.
- ✓ skin color – categorical variable: white, black, Mestizo, Asian, Native American.
- ✓ educational level - discrete variable: completed years of schooling of the subject.
- ✓ father's education – as above, for the subject's father.
- ✓ occupational exposure to dust: duration of exposure, intensity of contact, frequency of contact and type of work.
- ✓ smoking history – daily amount, age at beginning and stopping, type of cigarette, etc
- ✓ passive smoking – intensity and duration of exposure at home
- ✓ domestic exposure to coal and biomass smoke – exposure to smoke from cooking and heating;
- ✓ hospital admissions – whether or not the subject was hospitalized due to a respiratory illness during childhood;
- ✓ family history of lung disease - chronic bronchitis, emphysema, or COPD.

The subject's anthropometric status (weight, height, and abdominal circumference) was measured using standardized methods and the instruments described below. Body mass index was calculated.

2.4. Exclusion criteria

The general exclusion criteria for the study were mental disease and institutionalization. In the Venezuelan survey, 6 subjects were excluded due to these conditions.

Exclusion criteria for spirometry – presence in the last three months of thoracic or abdominal surgery, heart attack, eye surgery (or retinal detachment), hospitalization for any heart problem, current treatment for tuberculosis, self-reported pregnancy or pulse rate above 120 beats/minute. Forty two subjects were excluded due to these criteria.

2.5. Instruments and examinations

2.5.1. Questionnaire - the questionnaire was a composite that included sections of the following questionnaires: ATS/DLD (Ferris, 1978), ECRHS II, Lung Health Study (LHS) and SF-12 were also added to assess overall health status. A copy of the questionnaire is presented in Annex 1 and the manual of instructions in Annex 2.

2.5.2. Height measurement. A portable Seca[®] stadiometer (precision 0.1 cm) was used for measuring height. The technique was that recommended by Lohman (Lohman, 1988). Subjects did not wear shoes. They were asked to stand with their feet placed on top of the drawing at the bottom of the stadiometer, and to keep their heads straight in the Francfort plane while their height was checked.

2.5.3. Weight. An electronic Seca[®] weight scale (precision 200 g) was used. Subjects were weighted without shoes and wearing light clothes.

2.5.4. Waist circumference. An inextensible Fiberglass[®] tape (precision 0.1 cm) was used. Firstly the interviewers identified the midpoint between the last rib and the iliac crest; then the tape was placed around the waist crossing this midpoint. The measurement was read while the tape was held, neither be too tight nor too loose.

2.5.5. Spirometry. A portable, battery operated, ultrasound transit-time based spirometer (Easy-One from NDD) was used. The spirometers had their calibration checked daily with a three-liter syringe before being used in the field. The spirometers stored up to 400 test results in a memory chip, which was downloaded regularly. The initial evaluation was performed immediately after a short questionnaire established whether the subject was eligible for this procedure (ascertainment of eligibility included measurement of the subject's pulse rate), and after anthropometric examination was completed. Subjects then performed a number of attempts until these resulted in three ATS acceptable maneuvers, with FVC and FEV1 reproducible to 150 ml (see quality control for spirometry in Annex 3). A bronchodilator (salbutamol 200 mcg) was then administered by inhalation, and the test was repeated 15 minutes later, with the same criteria. All spirometric examinations were carried out with the subject seated, wearing a nose clip and a disposable mouthpiece.

The measurements of weight, height and waist circumference were carried out twice on each subject, and the average value was used.

2.6. Personnel and training

The training team was composed by the main coordinator of the study, two experts in spirometry (one from Mexico and one from Montevideo), the local principal investigators, three fieldwork supervisors from Venezuela and one from Uruguay, and 11 interviewers. Training lasted one week. In addition to the initial training sessions, the local supervisors continued to train interviewers whose performance in the standardization sessions was not optimal, until it became satisfactory. The spirometry expert from Montevideo and the Uruguayan fieldwork supervisor remained in Caracas for the first half of the fieldwork period. The following criteria were used to ensure that training was adequate:

- ✓ Anthropometry: the acceptable levels of intra- and inter-observer variability for waist circumference was 1.0 cm and that for height was 0.2 cm (Habicht, 1974).
- ✓ Spirometry: interviewers performed several measurements on different subjects and were then submitted to a formal examination including two complete tests. If they succeeded in these tests, they were certified.

- ✓ Questionnaires: after having carried out several interviews with both health and diseased subjects, interviewers had to carry out an interview in the presence of a supervisor and were approved if their performance was satisfactory.

2.7. Logistics of field work

The fieldwork lasted from September 4 to November 29, 2004. The study team included 11 trained interviewers, two local principal investigators, four fieldwork supervisors, one study coordinator, two spirometry supervisors and a secretary. During the first half of the survey, technical supervision of fieldwork and spirometric quality control were in charge of professionals from the Uruguayan Platino team.

All field methods were tested in a pilot study carried out from 2-3 September 2004 in a lower middle-class area in Caracas, near the study's headquarters.

The logistic of the fieldwork included several steps, beginning with an early contact with the selected households in order to provide information about the study and to locate adults within the age range of interest. Special pamphlets were printed and distributed with detailed letters. Formal approval of police and health authorities was obtained. Mass media support (newspapers, radio and TV) contributed to stimulate the participation of the target population.

During the initial visit, eligible subjects were informed that a study supervisor would contact them in order to arrange the best time for the interview and examination. Because the sampling scheme did not allow replacement of either households or subjects, an intensive regime of visits was planned in order to reduce the rate of refusals. Fieldwork was started in lower and middle income areas of the city, because greater difficulty was foreseen in high-income areas.

Early in the morning, interviewers visited the study headquarters to calibrate the equipment and to receive a list of the households to be visited on that day. On that occasion, spirometry results obtained in the previous day were downloaded to the computer.

Each interviewer carried a backpack containing all the equipment. Depending on the distance between the headquarters and the census tract to be visited, interviewers traveled by bus, car, or a University van.

2.8. Quality control

Spirometry – After each test, the automated spirometer provides an evaluation of the quality of readings, based on the repeatability of the three “best” curves (on average each subject performed 5.6 maneuvers pre bronchodilator (BD) and 5.1 post BD). The aim was to obtain a grade “A” test according to this on-the-spot evaluation. During data collection, all spirometry results were sent weekly to Mexico by email. The Mexican team analyzed their quality and provided weekly quality control reports with assessments of each individual interviewer. At the same time the local supervisor of the study checked all spirometries daily, and worked with the interviewers to correct any inaccuracies detected. Annex 3 shows results of the regular quality control procedures, which confirmed that average measurement quality was 80% or higher throughout the study period.

Interviews – 10% of the interviews were repeated by the supervisors. Within a week after the interview, a supervisor contacted the subject interviewed and repeated six questions from the main questionnaire to assess reliability.

Anthropometry – Half way through the fieldwork (end of second month), all the interviewers underwent refresher training in anthropometry, followed by a second round of standardization sessions.

2.10. Ethical considerations

The protocol was approved by the appropriate ethical committee (Comité Independiente de Revisión de Estudios Clínicos). Only subjects who signed the informed consent form took part in the study. The disposable mouthpiece and spacers were given to each subject. The results of spirometries were mailed to each respondent and those with abnormal results were referred to health services. A telephone hotline was provided, and two specialists in adult respiratory diseases were available for answering questions by subjects diagnosed during the survey.

2.11. Processing of data

All questionnaires were photocopied and the originals were sent to the Coordinating Centre (CC) in Brazil, while the copy remained in Caracas. In the CC, all questionnaires were revised, open answers were coded and data were entered twice in an Epi-Info database.

The spirometry results were sent to Mexico and entered in a Stata database. After spirometry results were cleaned and edited, the database was sent to the CC and linked to the questionnaire database. A full copy of the clean dataset was sent to the study site in Caracas, and the original database was analyzed in the CC.

2.12. Analysis

Analyses were carried out using the Stata program. These included descriptive analyses of the outcome variables and of risk factor prevalence, bivariate analyses and multivariate analyses. For the multivariate analyses, Poisson regression (Barros, 2003) was used to provide estimates of prevalence ratios and their 95% confidence intervals. Analyses were carried out according to a previously defined conceptual model which took into account the hierarchical relationships between risk factors (Victora, 1997). For example, demographic and social factors were considered as distal determinants while smoking and exposure to pollution were considered as proximate determinants (see Results section). All analyses took into account the cluster sampling procedure. Confounding variables were kept in the model if they had reached a P level of 0.20 or lower in the likelihood ratio test; the 0.05 P level was used for identifying significant risk factors. Tests for linear trend were used when appropriate.

3. RESULTS

3.1. Response rates and number of individuals included

Figure 3 shows the number of households and subjects included in the different phases of the study. Non-response rates were 20% at the household level, 11.1% at the individual questionnaire level, and 1.2% for spirometry. The overall rate of non-response was 30.0%, obtained by multiplying the response rates.




Figure 3. Number of households and individuals included in the different phases of the study.

Even for the 170 non-responders, we tried to obtain information on sex, age and smoking status; 49 (29%) answered these questions. This information was then extrapolated to the 170 non-responders. Table 3 shows the percentage of non-response by sex, age and smoking status.

Table 3. Percentage of non-response by sex, age and smoking status.

| <i>Variable</i> | <i>% individual non-response</i> |
|-------------------------------|----------------------------------|
| Sex | |
| Males | 14.4% |
| Females | 9.2% |
| Age | |
| 40-49 | 11.2% |
| 50-59 | 12.1% |
| ≥ 60 | 11.7% |
| Current smoking status | |
| No | 10.0% |
| Yes | 13.8% |

3.2. Prevalence of COPD according to different criteria

3.2.1. Spirometric criteria

As discussed in the Methods section, several different spirometric criteria were used to estimate COPD prevalence. Figure 4 shows these estimates and their 95% confidence intervals, which take into account the cluster sample design.




Figure 4. Prevalence of COPD based on different spirometric criteria.

The fixed ratio (FR) criterion showed the highest prevalence, of 12.1%, followed by the ERS (11.5%), ATS94 (10.0%) and GOLD (6.2%) definitions. All criteria, except for the fixed ratio definition, are based on a comparison with a set of standard function curves. The NHANES Mexican-American reference values were used for this purpose.

The design effect (deff) - an estimate of how much the cluster sample affected the variability of the measures – was calculated for the fixed ratio and GOLD estimates. The values obtained were 1.02 and 0.99, respectively. Design effects substantially greater than 1.0 are of concern, but was not the case for these outcome measures. In the sample size calculations for the present study, the design effect had been assumed to be equal to 1.5.

3.2.2 Clinical criteria

Symptoms related to COPD were also studied (Figure 5).




Figure 5. Prevalence of reported respiratory symptoms.

The prevalence of chronic bronchitis according to reported symptoms - cough with phlegm for at least 3 months a year in the last 2 years – was equal to 2.8%. Breathlessness due to exercise, and wheezing in the last 12 months were reported, respectively, by 50.6% and 18.5% of all subjects (Figure 5).

When 10% of the sample subjects were re-interviewed within one week of the original interview, it was possible to estimate the reliability of the information provided on symptoms. Kappa statistics were equal to 0.45 for cough and 0.50 for sputum, showing that agreement was intermediate.

Figure 6 shows the prevalence of reported medical diagnoses of bronchitis, emphysema, asthma and COPD. All conditions, except asthma, were reported by fewer than

3% of those interviewed. A medical diagnosis of chronic bronchitis, emphysema or COPD was reported by 3.8% of all subjects.




Figure 6. Prevalence of reported medical diagnoses of lung conditions.

3.3. Comparison of clinical and spirometric criteria

The availability of clinical and spirometric results for the same subjects allowed us to compare how these diagnoses relate to one another. Using the FR result as the gold standard, table 5 shows that the sensitivity of clinical bronchitis symptoms was 7.0% and its specificity 98.0%. Positive and negative predictive values were 32.4% and 88.4%, respectively.

Table 5. Comparison of COPD classification (fixed ratio criterion) and symptoms of chronic bronchitis (cough plus sputum for at least 3 months a year, for at least 2 years).

| <i>Prevalence of chronic bronchitis symptoms through questionnaire</i> | <i>Prevalence of COPD (fixed ratio)</i> | | <i>Total</i> |
|--|---|---------------|--------------|
| | <i>Present</i> | <i>Absent</i> | |
| Present | 11 | 23 | 34 |
| Absent | 146 | 1113 | 1259 |
| Total | 157 | 1136 | 1293 |

Similar results were obtained when clinical symptoms were compared to the GOLD criterion (Table 6). Sensitivity was 11.3% and specificity 97.9%; positive and negative predictive values were 26.5% and 94.4%, respectively.

Table 6. Comparison of the spirometric COPD classification (GOLD criterion) and the symptoms of chronic bronchitis (cough plus sputum for at least 3 months a year, for at least 2 years).

| <i>Prevalence of chronic bronchitis symptoms through questionnaire</i> | <i>Prevalence of COPD (GOLD - NHANES reference)</i> | | <i>Total</i> |
|--|---|---------------|--------------|
| | <i>Present</i> | <i>Absent</i> | |
| Present | 9 | 25 | 34 |
| Absent | 71 | 1188 | 1259 |
| Total | 80 | 1213 | 1293 |

These analyses were repeated for self-reported COPD, defined as either chronic bronchitis or breathlessness, or both. Sensitivity increased from 7.0% to 27.8%, but specificity decreased from 98.0% to 62.4% (Table 7). The positive predictive value was 9.1% and the negative predictive value 86.4%.

Table 7. Comparison of the spirometric COPD classification (FR criterion) and reported symptoms of chronic bronchitis (cough plus sputum for at least 3 months a year, for at least 2 years) and/or breathlessness.

| <i>Prevalence of symptoms of chronic bronchitis and/or breathlessness through questionnaire</i> | <i>Prevalence of COPD (FR criterion)</i> | | <i>Total</i> |
|---|--|---------------|--------------|
| | <i>Present</i> | <i>Absent</i> | |
| Present | 42 | 419 | 461 |
| Absent | 109 | 695 | 804 |
| Total | 151 | 1114 | 1265 |

For the GOLD criterion, the sensitivity of self-reported COPD was 51.0% and its specificity 100.0% (Table 8). The positive and negative predictive values were respectively 100.0% and 93.7%.

Table 8. Comparison of the spirometric COPD classification (GOLD criterion) and reported symptoms of chronic bronchitis (cough plus sputum for at least 3 months a year, for at least 2 years) and/or breathlessness.

| <i>Prevalence of symptoms of chronic bronchitis and/or breathlessness through questionnaire</i> | <i>Prevalence of COPD (GOLD – NHANES reference)</i> | | <i>Total</i> |
|---|---|---------------|--------------|
| | <i>Present</i> | <i>Absent</i> | |
| Present | 80 | 0 | 80 |
| Absent | 77 | 1136 | 1213 |
| Total | 157 | 1136 | 1293 |

Therefore, diagnoses based on clinical symptoms grossly failed to identify the vast majority of subjects on whom COPD was diagnosed by spirometry. On the other hand, most subjects with normal spirometry do not report any symptoms. Considering both symptoms of chronic bronchitis and breathlessness, sensitivity increased but specificity decreased. The reduction in specificity was partly due to the fact that breathlessness is often reported by asthmatic subjects, who performed well in the spirometry test after the use of bronchodilators.

Of 632 subjects who reported breathlessness, 189 (29.9%) presented a change in FEV1 post-bronchodilator use greater or equal than 12% (or 200 ml) or had a medical

diagnosis of asthma, thus suggesting the presence of asthma. This explains why the specificity of the combined diagnosis (Tables 7 and 8) was sharply reduced.

3.4. Risk factors for COPD

3.4.1. Distribution of the sample according to risk factors

Information was collected on several risk factors for COPD. Table 9 shows the demographic and socioeconomic risk factors, while Table 10 shows all the remaining independent variables.

More than 65% of all subjects were female, as was expected given the greater longevity of women. The average age was 55.1 years (SD 11.2). Most subjects classified themselves as Mestizos, followed by Whites and Blacks. There were very few Asians and Indians. Approximately 1/12 reported a family history (parents, siblings or children) of bronchitis, emphysema or COPD.

Two socioeconomic variables were investigated: schooling of the subjects themselves and of their fathers, as a proxy for the social class of their family. The average length of schooling of the studied subjects was 7.4 years (SD 4.3). More than 45% of the subjects were unable to inform about their fathers' schooling level, and about one third reported that their fathers had never attended school.

About 30% of the subjects were smokers, and a further 29%, ex-smokers. Current smokers accounted for 33.8% of the men and 25.7% of the women. When 10% of the sample was re-interviewed for quality control, the kappa statistic for smoking was equal to 0.93, showing high repeatability. Lifetime smoking was also assessed; 1/3 of all subjects informed having smoked more than 10 pack-years. The prevalence of reported passive smoking in the subject's home in the previous two weeks was 39%.

More than 30% of all subjects presented values of waist circumference above the recommended cut-off (88 cm for females and 102 cm for males). Overweight and obese subjects ($BMI \geq 25 \text{ kg/m}^2$) comprised almost 2/3 of the sample. The prevalence of obesity ($BMI \geq 30 \text{ kg/m}^2$) was 22.4% in males and 26.9% in females. Only 1.8% of all subjects reported having been admitted to a hospital due to a respiratory illness during childhood. Exposure to dust in the workplace for 10 years or more was reported by 19.8%.

Four sources of domestic smoke were studied: coal was used for cooking by 11.9% of all subjects and for heating by 0.4%; the corresponding exposures to biomass (mainly

wood) were 36.4% and 0.7%. These variables were collapsed into two: exposure to coal and exposure to domestic biomass fuels.

Table 9. Description of the sample according to demographic and socioeconomic variables.

| <i>Variable</i> | <i>Percentage</i> |
|--|-------------------|
| Sex | |
| Men | 34.9% |
| Women | 65.1% |
| Age | |
| 40-49 | 40.4% |
| 50-59 | 29.2% |
| ≥ 60 | 30.4% |
| Skin color / ethnicity | |
| White | 35.6% |
| Mestizo | 52.1% |
| Indian | 0.7% |
| Black | 11.2% |
| Asian | 0.4% |
| Family history of COPD, bronchitis or emphysema | |
| No | 91.9% |
| Yes | 8.1% |
| Schooling level (years) | |
| 0-2 | 10.8% |
| 3-4 | 11.9% |
| 5-8 | 42.8% |
| ≥ 9 | 34.5% |
| Schooling of the father | |
| None | 29.1% |
| Some | 25.8% |
| Does not know | 45.1% |

Table 10. Description of the sample according to behavioral, anthropometric and environmental variables.

| <i>Variable</i> | <i>Percentage</i> |
|--|-------------------|
| Smoking status | |
| Never smoked | 42.2% |
| Ex-smoker | 29.3% |
| Current smoker | 28.5% |
| Lifetime cigarettes smoked * | |
| Never smoked | 42.5% |
| ≤1 pack-years | 3.7% |
| 1.1-10 pack-years | 21.6% |
| >10 pack-years | 32.2% |
| Passive smoking | |
| No | 60.6% |
| Yes | 39.4% |
| Hospital admission for respiratory illness during childhood | |
| No | 98.2% |
| Yes | 1.8% |
| Lifetime exposure to dust in workplace | |
| Never | 59.3% |
| 1-9 years | 20.9% |
| ≥ 10 years | 19.8% |
| Exposure to coal stove for cooking or heating | |
| No | 90.3% |
| Yes | 9.7% |
| Exposure to biomass stove for cooking or heating | |
| No | 70.7% |
| Yes | 29.3% |
| Waist circumference | |
| Below cut-off | 67.4% |
| Above cut-off (≥88 cm for females or ≥102 for males) | 32.6% |
| Body mass index (kg/m²) | |
| <18.5 | 1.9% |
| 18.5 – 24.9 | 29.5% |
| 25 – 29.9 | 43.3% |
| ≥ 30 | 25.3% |

3.4.2. Crude analyses of main risk factors

Table 11 shows the prevalence of 11 outcomes related to pulmonary conditions, according to the categories of the four main risk factors under study: gender, age, smoking and schooling. All analyses took the clustering of the sample into account.

It is important to bear in mind that, as stated in the original proposal of the study, analyses of risk factors for COPD were planned for the pooled dataset including results from the other participating centers. The statistical power of the comparisons that are reported below is therefore quite low, and some important effects may fail to reach significant levels. For this reason, we have opted to highlight in the next section not only statistically significant results with a $P < 0.05$ but also results with P levels from 0.05 to 0.2, because the latter may well become significant when data from all participating sites are pooled in the final analyses. The current results, therefore, must be interpreted with caution.

Gender

Men performed less well than women according to all spirometric criteria (Table 11), but the gender difference was only significant according to the FR and GOLD criteria. One should bear in mind that the equations used for assessing spirometric results were already stratified by sex.

In terms of symptoms, women were more likely to report breathlessness. Women more often reported a medical diagnosis of asthma, but men reported more medical diagnosis of COPD. Therefore, males tended to have higher prevalence of spirometric diagnoses, but there were no clear gender differences for conditions with a medical diagnosis, except for asthma, which tended to be more common among women, and COPD, which tended to be more common among men. This difference may be explained by the variability in care-seeking patterns by gender.

Age

As expected, the prevalence of spirometric conditions increased with age (Table 11), despite the fact that the reference curves already took age into account. Chronic bronchitis also tended to increase with age. In terms of medical diagnoses, emphysema, chronic bronchitis and COPD showed a significant increase with age.

Smoking

The prevalence of COPD was higher among smokers and ex-smokers relative to non-smokers for all spirometric criteria. Symptoms of breathlessness were more common among former smokers. Wheezing symptoms were more likely among current smokers. Medical diagnosis of COPD was higher among former smokers than the other groups.

Schooling

The number of years of formal education was not associated with spirometric results. The only significant association was an inverse relationship between symptoms of breathlessness and years of schooling (Table 11).

Table 11. Prevalence of selected pulmonary outcomes according to proposed risk factors.

| | <i>Spirometric criteria</i> | | | | <i>Symptoms</i> | | | <i>Medical diagnosis</i> | | | |
|--------------------|-----------------------------|-------------------|-------------------|----------------|-------------------|-----------------------|-----------------|--------------------------|------------------|-------------------|-------------------|
| | <i>FR</i> | <i>GOLD</i> | <i>ATS</i> | <i>ERS</i> | <i>CB</i> | <i>Breathlessness</i> | <i>Wheezing</i> | <i>CB</i> | <i>Emphysema</i> | <i>Asthma</i> | <i>COPD</i> |
| Sex* | <i>P=0.002</i> | <i>P=0.05</i> | <i>P=0.13</i> | <i>P=0.93</i> | <i>P=0.37</i> | <i>P<0.001</i> | <i>P=0.53</i> | <i>P=0.18</i> | <i>P=0.71</i> | <i>P<0.001</i> | <i>P=0.04</i> |
| Males | 15.7% | 8.2% | 11.8% | 11.6% | 3.4% | 43.2% | 17.5% | 1.5% | 2.1% | 5.5% | 0.8% |
| Females | 10.2% | 5.1% | 9.0% | 11.4% | 2.5% | 54.5% | 19.0% | 2.4% | 1.8% | 13.4% | 0.1% |
| Age# | <i>P<0.001</i> | <i>P<0.001</i> | <i>P<0.001</i> | <i>P=0.001</i> | <i>P<0.001</i> | <i>P=0.45</i> | <i>P=0.20</i> | <i>P=0.01</i> | <i>P=0.005</i> | <i>P=0.21</i> | <i>P<0.001</i> |
| 40-49 | 5.4% | 2.9% | 6.7% | 7.7% | 1.2% | 48.8% | 17.0% | 1.0% | 0.8% | 9.6% | 0.0% |
| 50-59 | 9.8% | 4.8% | 9.3% | 11.2% | 2.9% | 50.8% | 18.3% | 1.6% | 1.6% | 9.3% | 0.0% |
| 60-94 | 23.4% | 12.0% | 15.0% | 16.8% | 4.3% | 51.4% | 20.6% | 3.8% | 3.6% | 12.2% | 1.0% |
| Smoking* | <i>P<0.001</i> | <i>P=0.002</i> | <i>P=0.001</i> | <i>P=0.001</i> | <i>P=0.52</i> | <i>P=0.02</i> | <i>P=0.02</i> | <i>P=0.87</i> | <i>P=0.18</i> | <i>P=0.09</i> | <i>P<0.001</i> |
| Never | 6.6% | 2.6% | 6.2% | 7.5% | 2.4% | 48.4% | 15.7% | 1.8% | 1.1% | 11.7% | 0.2% |
| Former | 16.9% | 9.4% | 11.6% | 13.7% | 3.5% | 55.8% | 18.6% | 2.3% | 3.0% | 12.1% | 1.0% |
| Current | 15.4% | 8.2% | 13.9% | 15.0% | 2.6% | 48.6% | 22.5% | 2.3% | 2.1% | 7.5% | 0.0% |
| Schooling (years)# | <i>P=0.11</i> | <i>P=0.47</i> | <i>P=0.23</i> | <i>P=0.49</i> | <i>P=0.17</i> | <i>P<0.001</i> | <i>P=0.16</i> | <i>P=0.51</i> | <i>P=0.24</i> | <i>P=0.42</i> | <i>P=0.99</i> |
| 0-2 | 16.2% | 6.2% | 13.3% | 12.5% | 3.4% | 61.7% | 21.8% | 1.4% | 0.7% | 17.7% | 0.7% |
| 3-4 | 13.7% | 8.5% | 9.8% | 11.8% | 3.7% | 55.7% | 19.9% | 1.2% | 0.6% | 8.1% | 0.0% |
| 5-8 | 12.0% | 6.1% | 10.2% | 12.0% | 3.1% | 51.1% | 19.5% | 2.4% | 2.8% | 8.4% | 0.3% |
| ≥9 | 10.6% | 5.5% | 8.9% | 10.4% | 1.9% | 44.8% | 15.8% | 2.1% | 1.7% | 12.0% | 0.4% |
| All subjects | 12.1% | 6.2% | 10.0% | 11.5% | 2.8% | 50.6% | 18.5% | 2.1% | 1.9% | 10.6% | 0.4% |
| Number in sample | 1293 | 1293 | 1290 | 1290 | 1357 | 1338 | 1357 | 1357 | 1357 | 1357 | 1356 |

* P-values calculated using the Wald test for heterogeneity

P-values calculated using the Wald test for trend

3.4.3. Additional crude analyses

The analyses shown in the preceding sections demonstrated that reported symptoms and medical diagnoses were not reliable and failed to show associations with well-known determinants of poor lung function. Thus, the detailed analyses of other risk factors were restricted to two spirometric outcomes: GOLD and FR. The GOLD criteria are used because they are the most frequently employed in the international literature, and FR has the advantage of not requiring the use of reference curves. Results according to the ATS and ERS criteria are shown in Annex 4.

FR criteria

Table 12 shows the unadjusted prevalence of COPD according to FR criteria (COPD/FR), as well as the corresponding prevalence ratios and confidence intervals, for demographic and socioeconomic risk factors. Table 13 shows the same information for the behavioral and environmental risk factors.

Men were 54% more likely than women to present with COPD/FR. Individuals aged 60 or over were more than four times more likely to present COPD/FR than those aged 40-49 years. Family history of COPD, bronchitis or emphysema was a risk factor for COPD/FR. Schooling was not associated with COPD/FR. Paternal schooling (at least some) was associated with a reduced risk of COPD/FR.

Former and current smokers were 2.3-2.5 times more likely to present COPD/FR, and individuals with lifetime consumption above 10 pack-years presented a 3-fold greater likelihood of having COPD/FR. Reported passive smoking in the past two weeks was not significantly associated with the outcome.

No associations were found between COPD/FR and hospital admissions due to respiratory disease in childhood, nor with exposure to domestic biomass smoke or exposure to dust at the workplace.

GOLD criteria

The unadjusted analyses of risk factors for COPD using the GOLD criteria (COPD/GOLD) are presented in Tables 14 and 15. Most results were very similar to those obtained with COPD/FR, although P levels in Tables 14 and 15 tended to be higher than those in Tables 12 and 13 because prevalence of COPD/GOLD is lower than that of COPD/FR, and therefore statistical power is reduced.

COPD/GOLD was 61% more frequent in men than women, and was positively associated with age. No associations were found according to family history of COPD, bronchitis or emphysema or schooling (individual or paternal).

Smoking (either current or past) was related to the prevalence of COPD/GOLD, and individuals with lifetime consumption above 10 pack-years were 4.4 times more likely to present COPD/GOLD. Those admitted to hospital due to respiratory problems in childhood were more likely to present COPD/GOLD. All other variables were not significantly related to the prevalence of COPD/GOLD.

Table 12. Crude analysis between COPD (fixed ratio criteria) and the demographic and socioeconomic independent variables

| <i>Variable</i> | <i>% COPD Fixed Ratio Criteria</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|--|--|-------------------|----------------|
| Sex | | | 0.002* |
| Men | 15.7% | 1.54 (1.74; 2.02) | |
| Women | 10.2% | 1.00 | |
| Age | | | <0.001# |
| 40-49 | 5.4% | 1.00 | |
| 50-59 | 9.8% | 1.82 (1.22; 2.73) | |
| ≥ 60 | 23.4% | 4.36 (2.78; 6.85) | |
| Skin color / ethnicity | | | <0.001* |
| White | 13.5% | 1.00 | |
| Mestizo | 12.0% | 0.89 (0.63; 1.27) | |
| Indian | 22.2% | 1.65 (0.46; 6.01) | |
| Black | 8.5% | 0.63 (0.32; 1.22) | |
| Asian | 0.0% | - | |
| Family history of COPD, bronchitis or emphysema | | | 0.05* |
| No | 11.6% | 1.00 | |
| Yes | 18.3% | 1.57 (1.00; 2.49) | |
| Schooling level | | | 0.11# |
| 0-2 | 16.2% | 1.52 (0.88; 2.64) | |
| 3-4 | 13.7% | 1.30 (0.74; 2.26) | |
| 5-8 | 12.0% | 1.14 (0.77; 1.67) | |
| ≥ 9 | 10.6% | 1.00 | |
| Schooling of the father | | | 0.03* |
| None | 12.6% | 1.00 | |
| Some | 8.0% | 0.63 (0.40; 1.01) | |
| Does not know | 14.2% | 1.13 (0.86; 1.48) | |

* Wald test for heterogeneity

Wald test for trend

Table 13. Crude analysis between COPD (fixed ratio criteria) and the behavioral and environmental independent variables.

| <i>Variable</i> | <i>% COPD Fixed Ratio Criteria</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|--|--|-------------------|----------------|
| Smoking status | | | <0,001* |
| Never smoked | 6.6% | 1.00 | |
| Ex-smoker | 16.9% | 2.56 (1.76; 3.73) | |
| Current smoker | 15.4% | 2.33 (1.55; 3.52) | |
| Lifetime cigarettes smoked | | | <0.001# |
| Never smoked | 6.6% | 1.00 | |
| ≤1 pack-years | 8.5% | 1.28 (0.49; 3.36) | |
| 1.1-10 pack-years | 10.8% | 1.63 (1.04; 2.57) | |
| >10 pack-years | 20.7% | 3.12 (2.16; 4.51) | |
| Passive smoking | | | 0.47* |
| No | 11.5% | 1.00 | |
| Yes | 13.2% | 1.15 (0.79; 1.67) | |
| Hospital admission for respiratory illness during childhood | | | 0.53* |
| No | 12.1% | 1.00 | |
| Yes | 16.0% | 1.32 (0.55; 3.22) | |
| Lifetime exposure to dust at the workplace | | | 0.73# |
| Never | 12.3% | 1.00 | |
| 1-9 years | 10.2% | 0.83 (0.52; 1.30) | |
| ≥ 10 years | 13.8% | 1.12 (0.83; 1.51) | |
| Exposure to coal stove for cooking or heating | | | 0.72* |
| No | 12.3% | 1.00 | |
| Yes | 10.9% | 0.89 (0.46; 1.71) | |
| Exposure to biomass stove for cooking or heating | | | 0.25* |
| No | 11.5% | 1.00 | |
| Yes | 13.9% | 1.21 (0.87; 1.67) | |

* Wald test for heterogeneity

Wald test for trend

Table 14. Crude analysis between COPD (GOLD criteria) and the demographic and socioeconomic independent variables.

| <i>Variable</i> | <i>% COPD Gold Criteria</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|--|---------------------------------|--------------------|----------------|
| Sex | | | 0.05* |
| Men | 8.2% | 1.61 (1.00; 2.57) | |
| Women | 5.1% | 1.00 | |
| Age | | | <0.001# |
| 40-49 | 2.9% | 1.00 | |
| 50-59 | 4.8% | 1.66 (0.86; 3.19) | |
| ≥ 60 | 12.0% | 4.16 (2.35; 7.39) | |
| Skin color / ethnicity | | | <0.001* |
| White | 5.6% | 1.00 | |
| Mestizo | 6.4% | 1.13 (0.68; 1.87) | |
| Indian | 11.1% | 1.97 (0.26; 15.14) | |
| Black | 7.0% | 1.25 (0.53; 2.91) | |
| Asian | 0.0% | - | |
| Family history of COPD, bronchitis or emphysema | | | 0.35* |
| No | 6.0% | 1.00 | |
| Yes | 8.7% | 1.45 (0.66; 3.18) | |
| Schooling level | | | 0.47# |
| 0-2 | 6.2% | 1.12 (0.45; 2.76) | |
| 3-4 | 8.5% | 1.54 (0.83; 2.86) | |
| 5-8 | 6.1% | 1.11 (0.64; 1.91) | |
| ≥ 9 | 5.5% | 1.00 | |
| Schooling of the father | | | 0.21* |
| None | 6.6% | 1.00 | |
| Some | 4.2% | 0.63 (0.33; 1.23) | |
| Do not know | 7.1% | 1.08 (0.71; 1.65) | |

* Wald test for heterogeneity

Wald test for trend

Table 15. Crude analysis between COPD (GOLD criteria) and the behavioral and environmental independent variables.

| <i>Variable</i> | <i>% COPD Gold Criteria</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|--|---------------------------------|-------------------|----------------|
| Smoking status | | | 0.002* |
| Never smoked | 2.6% | 1.00 | |
| Ex-smoker | 9.4% | 3.66 (1.84; 7.31) | |
| Current smoker | 8.2% | 3.21 (1.56; 6.62) | |
| Lifetime cigarettes smoked | | | <0.001# |
| Never smoked | 2.6% | 1.00 | |
| ≤1 pack-years | 4.3% | 1.65 (0.36; 7.59) | |
| 1.1-10 pack-years | 5.8% | 2.23 (1.06; 4.73) | |
| >10 pack-years | 11.4% | 4.43 (2.25; 8.72) | |
| Passive smoking | | | 0.16* |
| No | 5.4% | 1.00 | |
| Yes | 7.5% | 1.39 (0.87; 2.23) | |
| Hospital admission for respiratory illness during childhood | | | 0.03* |
| No | 6.0% | 1.00 | |
| Yes | 16.0% | 2.67 (1.08; 6.62) | |
| Lifetime exposure to dust at the workplace | | | 0.94# |
| Never | 6.4% | 1.00 | |
| 1-9 years | 4.7% | 0.74 (0.41; 1.34) | |
| ≥ 10 years | 7.1% | 1.10 (0.69; 1.78) | |
| Exposure to coal stove for heating | | | 0.63* |
| No | 6.3% | 1.00 | |
| Yes | 5.0% | 0.80 (0.32; 2.03) | |
| Exposure to biomass stove for heating | | | 0.69* |
| No | 6.0% | 1.00 | |
| Yes | 6.7% | 1.11 (0.66; 1.85) | |

* Wald test for heterogeneity

Wald test for trend

3.4.4. Multivariable analyses

The multivariable analyses took into account four hierarchical levels of determination of the outcome (Victora, 1997) (Figure 7). The most distal level included sex, age, skin color and a family history of bronchitis, emphysema or COPD, which are biological characteristics that may influence other determinants of COPD. The second level includes schooling, which is mostly determined in childhood and adolescence. The third level incorporates exposures that refer to the subjects' earlier life: hospital admissions, exposure to dust in the workplace, and exposure to domestic smoke. The current exposure is smoking (level 4).

Due to high collinearity between smoking status (non, ex, current smoker) and lifetime exposure (pack-years), it was not possible to include both variables in the model and thus we opted for retaining lifetime exposure, because its association with the outcomes was stronger in the crude analyses. Paternal schooling was also not included in these analyses because of the high number of missing data.




Figure 7. Conceptual framework for guiding the multivariable analyses.

These analyses are presented separately for the FR and GOLD criteria.

FR criterion

Table 16 shows the results of the COPD/FR outcome. Male sex, higher age and family history of respiratory disease were associated with higher COPD/FR prevalence. The association between COPD/FR and skin color must be interpreted with caution due to small numbers.

In the second level of analyses, schooling was not associated with COPD/FR. History of respiratory admission, exposure to coal or biomass smoke and exposure to dust at the workplace were not significantly related to COPD/FR.

Individuals with lifetime cigarette consumption above 10 pack-years were 153% more likely to present COPD/FR than never smokers.

Table 16. Adjusted analysis between COPD (fixed ratio criteria) and the independent variables.

| <i>Level</i> ^{..} | <i>Variable</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|----------------------------|--|-------------------|----------------|
| 1 | Sex | | 0.001* |
| | Men | 1.58 (1.21; 2.07) | |
| | Women | 1.00 | |
| 1 | Age | | <0.001# |
| | 40-49 | 1.00 | |
| | 50-59 | 1.84 (1.24; 2.74) | |
| | ≥ 60 | 4.34 (2.80; 6.72) | |
| 1 | Skin color / ethnicity | | <0.001* |
| | White | 1.00 | |
| | Mestizo | 0.96 (0.70; 1.34) | |
| | Native American | 1.64 (0.59; 4.52) | |
| | Black | 0.71 (0.38; 1.35) | |
| | Asian | - | |
| 1 | Family history of COPD, bronchitis or emphysema | | 0.02* |
| | No | 1.00 | |
| | Yes | 1.74 (1.09; 2.80) | |
| 2 | Schooling level | | 0.88# |
| | 0-2 | 1.01 (0.59; 1.72) | |
| | 3-4 | 1.02 (0.62; 1.67) | |
| | 5-8 | 0.93 (0.49; 1.77) | |
| | ≥ 9 | 1.00 | |
| 3 | Hospital admission for respiratory illness during childhood | | 0.73* |
| | No | 1.00 | |
| | Yes | 1.18 (0.46; 3.03) | |
| 3 | Lifetime exposure to dust at the work-place | | 0.60# |
| | Never | 1.00 | |
| | 1-9 years | 0.86 (0.56; 1.34) | |
| | ≥ 10 years | 0.93 (0.65; 1.32) | |
| 3 | Exposure to coal stove for heating or cooking | | 0.51* |
| | No | 1.00 | |
| | Yes | 0.80 (0.42; 1.56) | |
| 3 | Exposure to biomass stove for heating or cooking | | 0.98* |
| | No | 1.00 | |
| | Yes | 1.00 (0.73; 1.36) | |
| 4 | Lifetime cigarettes smoked | | <0.001# |
| | Never smoked | 1.00 | |
| | ≤1 pack-years | 1.23 (0.47; 3.22) | |
| | 1.1-10 pack-years | 1.70 (1.09; 2.65) | |
| | >10 pack-years | 2.53 (1.78; 3.59) | |

* Wald test for heterogeneity # Wald test for trend .. Level of the variable in the hierarchical model

GOLD criterion

Table 17 shows the results of the multivariable analyses for the COPD/GOLD outcome. Men had a higher risk than women, but the difference was not statistically significant. Age was positively associated with the outcome, with a 4.5-fold increase for those aged 60 years or more relative to the 40-49 year age group. No associations were found with a family history of respiratory diseases. The association between COPD/GOLD and skin color must be interpreted with caution due to small numbers.

In the second level of the multivariable analyses, schooling was not associated with COPD/GOLD.

COPD/GOLD was not associated with coal or biomass smoke exposure, hospital admissions due to respiratory symptoms during childhood or workplace exposure to dust. Individuals with lifetime cigarette consumption above 10 pack-years presented a 278% greater likelihood of having COPD/GOLD.

These results were quite similar to those observed in the multivariable analyses of COPD/FR, as shown by the prevalence ratios in Tables 16 and 17. P levels for GOLD tended to be less significant because prevalence and therefore statistical power were smaller.

Table 17. Adjusted analysis between COPD (GOLD criteria) and the independent variables.

| <i>Level*</i> | <i>Variable</i> | <i>PR (CI95%)</i> | <i>P-value</i> |
|---------------|--|--------------------|----------------|
| 1 | Sex | | 0.06* |
| | Men | 1.58 (0.97; 2.57) | |
| | Women | 1.00 | |
| 1 | Age | | <0.001# |
| | 40-49 | 1.00 | |
| | 50-59 | 1.68 (0.88; 3.20) | |
| | ≥ 60 | 4.50 (2.60; 7.81) | |
| 1 | Skin color / ethnicity | | <0.001* |
| | White | 1.00 | |
| | Mestizo | 1.23 (0.75; 2.02) | |
| | Native American | 1.85 (0.28; 13.25) | |
| | Black | 1.38 (0.60; 3.18) | |
| | Asian | - | |
| 1 | Family history of COPD, bronchitis or emphysema | | 0.21* |
| | No | 1.00 | |
| | Yes | 1.65 (0.75; 3.62) | |
| 2 | Schooling level | | 0.41# |
| | 0-2 | 1.59 (0.67; 3.76) | |
| | 3-4 | 1.43 (0.63; 3.23) | |
| | 5-8 | 1.64 (0.72; 3.76) | |
| | ≥ 9 | 1.00 | |
| 3 | Lifetime exposure to dust at the work-place | | 0.48# |
| | Never | 1.00 | |
| | 1-9 years | 0.74 (0.43; 1.26) | |
| | ≥ 10 years | 0.88 (0.53; 1.45) | |
| 3 | Hospital admission for respiratory illness during childhood | | 0.04* |
| | No | 1.00 | |
| | Yes | 2.57 (1.03; 6.42) | |
| 3 | Exposure to biomass stove for heating or cooking | | 0.74* |
| | No | 1.00 | |
| | Yes | 0.92 (0.55; 1.54) | |
| 3 | Exposure to coal stove for heating or cooking | | 0.34* |
| | No | 1.00 | |
| | Yes | 0.66 (0.28; 1.57) | |
| 4 | Lifetime cigarettes smoked | | <0.001# |
| | Never smoked | 1.00 | |
| | ≤1 pack-years | 1.63 (0.36; 7.46) | |
| | 1.1-10 pack-years | 2.30 (1.12; 4.73) | |
| | >10 pack-years | 3.78 (2.00; 7.15) | |

* Wald test for heterogeneity # Wald test for trend * Level of the variable in the hierarchical model

3.4.5. COPD and anthropometry

Subjects whose waist circumference was above the cut-off points (88 cm for females and 102 cm for males) showed significant lower ($P < 0.001$) forced expiratory volume (FEV1) values than those with normal waist circumferences. While the average FEV1 was 2.65 (SD 0.69) for subjects below the cut-off point, it was 2.32 (SD 0.69) for those above. The same trend was observed for forced vital capacity (FVC), with averages of 3.38 (SD 0.83) and 2.96 (SD 0.81) for subjects below or above the cut-off points, respectively ($P < 0.001$). Thus, central adiposity was inversely related to lung function.

The association between BMI and COPD is summarized in Figure 8. According to both criteria, the prevalence of COPD was higher in the low-BMI group ($< 18.5 \text{ kg/m}^2$) and a decreased trend was observed in the remaining categories.




Figure 8. Relationship between COPD (FR and GOLD criteria) and body mass index (BMI).

3.5. Additional analyses

3.5.1. Co-morbidity

Table 18 shows the lifetime prevalence of medical diagnoses for some key conditions. Hypertension and “gastritis” were reported by over 20% of all subjects. Diabetes and heart problems were reported by 7-10%, and other conditions were less frequently reported. Given the subjective nature of this information, these variables should be interpreted with due caution.

One variable from this subset was chosen for the repeatability analyses. Lifetime history of a diagnosis of tuberculosis, when checked by a supervisor on a later occasion, resulted in a kappa coefficient of 1.00, showing perfect agreement between the original and repeat interviews. The kappa statistic was not calculated for the other conditions under study.

Table 18. Lifetime prevalence of selected medical diagnoses.

| <i>Condition</i> | <i>Prevalence</i> |
|------------------|-------------------|
| Hypertension | 30.0% |
| Gastritis | 22.8% |
| Heart problem | 10.0% |
| Diabetes | 7.1% |
| Tuberculosis | 0.9% |
| Stroke | 0.8% |
| Lung cancer | 0.0% |

Table 19 shows the associations between these reported diagnoses and COPD. History of tuberculosis was related to a higher risk of COPD/FR. Other diseases were not associated with COPD in these cross-sectional analyses.

Table 19. Prevalence of COPD according to co-morbidity.

| <i>Condition</i> | <i>COPD (FR criteria)</i> | | <i>COPD (GOLD criteria)</i> | |
|----------------------|---------------------------|----------|-----------------------------|----------|
| | <i>Prevalence</i> | <i>P</i> | <i>Prevalence</i> | <i>P</i> |
| Heart problem | | 0.17 | | 0.55 |
| Yes | 8.3% | | 7.4% | |
| No | 12.5% | | 6.1% | |
| Hypertension | | 0.82 | | 0.35 |
| Yes | 12.5% | | 7.2% | |
| No | 12.0% | | 5.8% | |
| Diabetes | | 0.10 | | 0.48 |
| Yes | 6.7% | | 4.4% | |
| No | 12.6% | | 6.3% | |
| Stroke | | 0.35 | | 0.44 |
| Yes | 22.2% | | 0.0% | |
| No | 12.1% | | 6.2% | |
| Tuberculosis | | 0.54 | | 0.10 |
| Yes | 18.2% | | 18.2% | |
| No | 12.1% | | 6.1% | |
| Gastritis | | 0.43 | | 0.66 |
| Yes | 13.5% | | 6.7% | |
| No | 11.8% | | 6.0% | |

3.5.2. Etiologic fractions

Information on the adjusted prevalence ratios (Tables 16 and 17) and on the frequency of different exposures (Tables 9 and 10), allowed us to estimate the etiologic fraction, or population attributable risk of COPD due to different exposures. This expresses the proportion of COPD cases in the community that would be prevented if the exposure was completely eradicated.

According to COPD/FR, the attributable risk for cigarette consumption above 10 pack-years is 33.0%, while it is 47.2% according to COPD/GOLD. Therefore, about one in 2-3 COPD cases would be prevented if all heavy smokers had never smoked.

3.5.3. Role of smoking in the gender differential in COPD

Male sex was associated with a higher risk of COPD, according to all spirometric criteria used. However, these associations were somewhat reduced after controlling for smoking status. The male/female prevalence ratio was 1.58 for COPD/FR, but when we control for smoking, the value is 1.27. For the COPD/GOLD indicator, the value decreased from 1.58 to 1.18. This shows that part of the excess in COPD among males is due to the fact that they smoke more often.

3.6. Medical management

Overall, 11.7% of all subjects (159 subjects) reported having used medicines for lung or respiratory problems in the previous 12 months (Table 20). The prevalence rates for COPD/FR positive and negative individuals were, respectively, 25.5% and 9.6% ($P<0.001$). Table 20 shows the medicines used more frequently.

Although influenza immunization is recommended for all COPD patients, only half (5.1%) of those who were COPD/FR positive reported being vaccinated in the previous year, compared to 3.2% of the remainder ($P=0.21$).

Subjects were asked if they had ever been submitted to spirometry. The lifetime frequency was 8.3%. Subjects with a diagnosis of COPD/FR presented a lifetime frequency of spirometry twice as high (17.8%) as those without a diagnosis (6.9%).

Table 20. Drugs used for respiratory problems in the past 12 months.

| <i>Drug</i> | <i>N</i> | <i>Percentage</i> |
|--------------------------------------|----------|-------------------|
| Mucolytic drugs | 57 | 23.4% |
| Bronchodilators | 31 | 12.7% |
| Bronchodilator plus inhaled steroids | 17 | 7.0% |
| Inhaled steroids | 9 | 3.7% |
| Others | 139 | 57.0% |
| Total | 244 | 100% |

3.7. Consequences of COPD

Table 21 compares COPD/FR positive and negative subjects in relation to several indicators of quality of life.

Table 21. Association between COPD/FR status and quality of life indicators.

| <i>Quality of life indicator</i> | <i>Prevalence according to COPD/FR status</i> | | <i>P</i> |
|---|---|-----------------|----------|
| | <i>Positive</i> | <i>Negative</i> | |
| Difficulty in carrying out moderate physical activities | 22.3% | 14.4% | 0.01 |
| Difficulty in carrying out intense physical activities | 31.9% | 17.7% | <0.001 |
| Any limitation due to physical health in the past year | 22.3% | 12.2% | <0.001 |
| Any limitation in the workplace due to physical health | 18.5% | 9.5% | 0.001 |
| Any limitation due to mental health in the past year | 16.6% | 14.4% | 0.46 |
| Any limitation in the workplace due to mental health | 12.7% | 10.0% | 0.30 |

3.8. Economic impact of COPD

Formal employment in the previous 12 months was reported by 51.8% individuals (39.5% among COPD/FR positive and 54.3% among the negative; $P < 0.001$). This difference disappeared, however, after adjustment for age, because both COPD and unemployment were more common among older subjects.

Among individuals who did not work in the previous year, 0.9% reported that this was due to lung disease.

Approximately one in nine individuals (7.5%) reported having limited leisure activities due to health problems. The percentages were 7.6% and 6.6% among COPD/FR positive and negative subjects, respectively ($P = 0.63$).

4. DISCUSSION

This is the final report from the fifth site to complete the PLATINO study. Previous reports described the surveys carried out in São Paulo (Menezes, Platino survey report - Brazilian sample, 2003), Mexico City (Menezes, Platino survey report - Mexican sample, 2004), Montevideo (Menezes, Platino survey report – Montevideo sample, 2004) and Santiago (Menezes, Platino survey report – Santiago sample, 2004).

The results presented here have a high level of precision for estimating the prevalence rates of COPD and of risk factors. The analyses of associations between exposures and disease, however, must be interpreted with caution because, for most comparisons being made, the required sample size will only be reached after data from the four other centers are pooled. Therefore, the present Discussion section will be limited to an outline of the main results. Associations that were not significant in this report may well become so when data from the other centers are incorporated.

4.1. Discussion of methodological issues

Given the size of the study area and the understandable reluctance of the population to welcome strangers, the response rate can be considered acceptable. There was no evidence that response rates differed according to sex, age or smoking status.

The study demonstrated that the spirometric examinations were acceptable to a vast majority of the sample, and 1.2% of those eligible failed to undergo the exam. Other positive aspects included the strong quality control and standardization protocols.

4.2. Discussion of main results

Prevalence estimates for COPD varied markedly according to the criteria used. When the study was designed, there was an a priori decision that COPD/FR would be the main outcome. This analysis showed that 12.1% of all subjects were affected, that is, about one in every eight individuals.

As expected, when the GOLD criteria were used, prevalence was markedly lower (6.2%) because this criterion is more specific. Also as expected, clinical symptoms showed wide variability and low validity. Medical diagnoses related to COPD (either chronic bronchitis, emphysema or COPD diagnoses) were reported by 3.8% of all subjects.

As mentioned, the analyses of risk factors were affected by the low statistical power of the study, which was designed as a collaborative study for which the final analyses will await data from other sites. Our preliminary adjusted analyses showed that male sex, older age, and lifetime smoking were significantly associated with COPD as assessed through the fixed ratio criteria. No other significant associations were detected. A comparison of our results with the medical literature will be carried out after the final analyses.

COPD was also associated with anthropometric variables (BMI and abdominal circumference), but this association must be interpreted with caution due to the possibility of reverse causality, that is, that pulmonary illness may have led to weight loss.

Regarding case-management most subjects with COPD take medication only when they have symptoms, which is inappropriate. Preventive interventions are also inadequate; for example, immunization against influenza in the previous year was rare among COPD positive subjects. Finally, diagnostic procedures were poor; the percentage of COPD/FR subjects who ever underwent spirometry was 18%.

We have also shown that presence of COPD affected the subjects' ability to carry out physical activities and that the disease had marked effects on most other indicators of quality of life. Further analyses will be carried out with data from all sites, not only considering each quality of life variable on its own, but also assessing the impact of COPD on composite indicators.

4.3. Conclusions

The Caracas survey confirmed results from other sites showing that the PLATINO protocol is able to recruit a representative sample of a large metropolitan area, with a high response rate. Standardization and quality control procedures ensured that data quality was appropriate. The data collection, analyses and report preparation were conducted in a timely fashion.

Finally, we would like to thank ALAT and BI for their continued support, as well as the sustained participation of the PLATINO Steering Committee.



5. REFERENCES

Hurd S. The Impact of DPOC on Lung Health Worldwide. *Chest* 2000;117(2):1-4.

Pauwels R. DPOC. The Scope of the Problem in Europe. *Chest* 2000;117(5):332-335.

Petty TL. Scope of the DPOC Problem in North America. *Chest* 2000;117(5):326-331.

Kish L. Survey Sampling. New York:John Wiley & Sons; 1965.

Silva NN. Amostragem Probabilística. São Paulo:EDUSP; 2ed. 2002.

Platino Project, 2002. Multi-Center Survey of COPD in Five Major Latin-American Cities; The "PLATINO" Survey; Proposal by Ana Menezes (on behalf of ALAT with support by Boehringer-Ingelheim).

Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L, Giuntini C. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. *Chest* 2000;117(5 Suppl 2):339S-345S.

GOLD, 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: Global Initiative for Chronic Obstructive Lung Disease, World Health Organization, National Heart, Lung, and Blood Institute; 2001. Available at: URL: <http://www.goldcopd.com/>.

ERS, 1993. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J* 1993;6(Suppl 16):5-40.

ATS, 1994. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 1995; 152: Suppl.5, 77-121.

U.S. Department of Health and Human Services, National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94 (1994).http://www.Cdc.gov.nchs/data/series/sr_01/sr01_032.pdf. Date accessed:20 December 2002.

Cyba Foundation Guest Symposium. Terminology, definition and classification of chronic pulmonary emphysema and related conditions. *Thorax* 1959; 14:286-99.

Ferris BG. Epidemiology standardization project. *Am Rev Respir Dis* 1978; 118:1-120.

ECRHS2 II. <http://www.ecrhs.org>. European Community Respiratory Health Survey II



LHS. http://www.bccr.ca/downloads/ci/lc02_questionnaire.doc

Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF12 Physical and Mental Health Summary Scales, 2nd edition. Boston, MA: The Health Institute, New England Medical Center, 1995.

Anthropometric Standardization Reference Manual. Lohman, Roche, Martorell, 1988.

Habicht JP. Estandarizacion de metodos epidemiologicos cuantitativos sobre el terreno. *Bol Of Sanit. Panam.*, 1974; Mayo: 375-84

Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. *BMC Medical Research Methodology* 2003, 3:21.

Victora CG, Huttly SR, Fuchs SC, Olinto MTA. The role of conceptual frameworks in epidemiological analysis: A hierarchical approach. *Int J Epidemiol* 1997; 26:224-7.

Pereira CAC, Barreto SP, Simões JG, Pereira FWL, Gerstler JG, Nakatani, J. Valores de referencia para espirometria em uma amostra da população brasileira adulta. *J Pneumol* 1992; 18:10-22).

Menezes AMB, Victora CG et al. Report presented to Boehringer-Ingelheim: “Platino Survey – Brazilian sample”, 2003.

Menezes AMB, Victora CG et al. Report presented to Boehringer-Ingelheim: “Platino Survey – Mexican sample”, 2004.

Menezes AMB, Victora CG et al. Report presented to Boehringer-Ingelheim: “Platino Survey – Uruguayan sample”, 2004.

Menezes AMB, Victora CG et al. Report presented to Boehringer-Ingelheim: “Platino Survey – Chilean sample”, 2004.

